A boxed warning is the strongest safety-related warning issued by the FDA
Most formulations are administered via subcutaneous injection (except oral semaglutide), typically weekly or daily depending on the specific medication, with dosing gradually increased over several weeks to minimize gastrointestinal side effects and optimize therapeutic response
The retatrutide dose schedule still recommends starting at a conservative dose to assess tolerance of the glucagon component, even if you were on high-dose tirzepatide previously
A depletion of 12.4 % of body weight was remarked with Semaglutide, notwithstanding race, age, sex, body mass index, or ethnicity
Check with your specific insurance plan about telehealth prescription coverage
In very rare cases, people taking oral semaglutide may experience more serious issues (see important safety information [this will be a link to other content]), but for most people side effects are mild and subside after they have been taking the medication for some time
